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Size and quality of randomised controlled trials in
head injury: review of published studies
Karen Dickinson, Frances Bunn, Reinhard Wentz, Phil Edwards, Ian Roberts
Abstract
Objective To assess whether trials in head injury are
large enough to avoid moderate random errors and
designed to avoid moderate biases.
Design All randomised controlled trials on the
treatment and rehabilitation of patients with head
injury published before December 1998 were surveyed.
Trials were identified from electronic databases, by
hand searching journals and conference proceedings,
and by contacting researchers. Data were extracted on
the number of participants, quality of concealment of
allocation, use of blinding, loss to follow up, and types
of participants, interventions, and outcome measures.
Results 279 reports were identified, containing
information on 208 separate trials. The average
number of participants per trial was 82, with no
evidence of increasing size over time. The total
number of randomised participants in the 203 trials
in which size was reported was 16 613. No trials were
large enough to detect reliably a 5% absolute
reduction in the risk of death or disability, and only
4% were large enough to detect an absolute reduction
of 10%. Concealment of allocation was adequate in 22
and inadequate or unclear in 25 of the 47 (23%) in
which it was reported. Of 126 trials assessing
disability, 111 reported the number of patients
followed up, and average loss to follow up was 19%.
Of trials measuring disability, 26 (21%) reported that
outcome assessors were blinded.
Conclusions Randomised trials in head injury are too
small and poorly designed to detect or refute reliably
moderate but clinically important benefits or hazards
of treatment. Limited funding for injury research and
unfamiliarity with issues of consent may have been
important obstacles.
Introduction
Worldwide, many millions of people are treated each
year for severe head injury. A substantial proportion
die, and many more are permanently disabled.1 Road
traffic accidents alone account for an estimated five
million head injuries each year.2 Reliable assessment of
the net benefits and hazards of various interventions
for the treatment and rehabilitation of head injuries
could be of considerable importance to public health.
If, for such a common problem, a widely
practicable treatment could be shown to reduce the
absolute risk of death and disability by “just” a few per
cent, this might affect the treatment of hundreds of
thousands of patients each year and protect thousands
from death or long term disability. To detect reductions
of this magnitude, however, both moderate random
errors and moderate biases must be avoided.3 This
means that randomised controlled trials of treatments
for head injury should be large enough to avoid mod›
erate random errors and designed in such a way that
moderate biases are also avoided.3 To assess the extent
to which randomised controlled trials in head injury
meet these criteria we conducted a survey of their size
and quality.
Methods
Inclusion criteria—We included all randomised con›
trolled trials of interventions in the treatment and
rehabilitation of head or brain injury contained within
the specialised register of the Cochrane Injuries Group
as of May 1999 and published before December 1998.
A randomised controlled trial was defined as a trial in
which the patients followed were assigned to one of
two (or more) interventions with random allocation or
some quasi›random method of allocation. There was
no language restriction.
Identification of studies—The injuries group main›
tains a specialised register of randomised controlled
trials in the prevention and treatment of and rehabili›
tation after traumatic injury. The register contains both
published and unpublished reports that have been
found by searches of electronic databases, hand
searching of key journals and conference proceedings,
and direct contact with trialists. The Cochrane
Controlled Trials Register (Cochrane Library 1999, issue
2) was searched to update the specialised register.
Medline (OVID) and PubMed, the most up to date ver›
sion of Medline, were searched in June 1999 to identify
further studies published up to December 1998. All
reports of randomised controlled trials in systematic
reviews prepared by the injuries group that referred to
head or brain injury trials were also included. A total of
605 records describing studies of head or brain injury
were identified. One collaborator (IR) scanned this list,
and 370 records referring to possible randomised con›
trolled studies were identified. Full copies of all these
reports were obtained and examined by one investiga›
tor (KD) to assess eligibility and for data extraction.
Excluded trials were checked by two investigators to
ensure that none were eligible.
Data extraction and data analysis—Data were
extracted on the date and language of publication,
number of randomised participants, method of
concealment of allocation, use of blinding, percentage
loss to follow up, and types of participants, interven›
tions, and outcome measures. The dimensions of
methodological quality assessed were those shown or
suspected to be associated with bias in estimates of
treatment effects.4 Reports published in languages
other than English were translated before data extrac›
tion. To test the accuracy of data extraction a 10% ran›
dom sample of reports was re›examined by FB and the
two sets of data were compared.
Statistical analysis—Trials were categorised accord›
ing to the number of randomised participants and a
histogram was plotted. We estimated the size of the
intervention effect that a trial of a given number of
participants would be able to detect at the 0.05 level of
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significance (á = 0.05) with 80% power (â = 0.2), assum›
ing a baseline risk (as estimated by control group event
rates) of 0.2.
Results
The combined search strategies identified 370 reports,
of which 279 were reports of randomised controlled
trials of interventions for head or brain injury. After
taking into account multiple reports of the same
randomised controlled trial we identified 208 discrete
randomised controlled trials. Most of the reports (86%)
were published as full journal articles, with the remain›
der published as abstracts in conference proceedings
(13%) or book chapters (2%). Most reports were
published in English (92%), with the remainder in
French (2%), Italian (2%), Chinese (1%), German (1%),
and Spanish (1%).
There was 90% agreement between assessors for
the number of randomised participants and for
method of concealment of allocation. In the trials in
which there was disagreement about the number of
randomised participants the numbers differed by only
one participant in each trial.
The number of randomised participants was
reported in 203 of the 208 trials. The total number of
randomised participants in the 203 trials was 16 613.
The average number of participants per trial was 82,
with no evidence of a trend towards larger trial size
over time. Interventions were classified into categories,
and table 1 shows the number of trials and number of
randomised participants for each category. The largest
trial was of additional information, advice, and support
to patients after head injury and included 1156 partici›
pants. The largest trial of a pharmacological agent was
of the aminosteroid tirilazad mesylate and included
1120 participants. The category of agents for which
there was the largest number of randomised partici›
pants was corticosteroids with 2515 participants.
The figure shows the size of trials with a curve giving
the magnitude of intervention effect (absolute risk
reduction) that a trial of that size would be able to detect
at the 0.05 level of significance (á = 0.05) with 80%
power (â = 0.2), with an assumed baseline risk of 0.2.
None of the existing trials could be expected to detect
reliably a difference in event rates of less than 5%, and
only 4% of trials would have been large enough to detect
a difference in event rates of less than 10%.
The method of concealment of allocation was
reported in only 47 (23%) of the trials. Of these,
concealment was judged to be adequate in 22 (11%)
and inadequate or unclear in 25. Table 2 shows the
methods of allocation used in the trials.
The Glasgow coma scale was used as an inclusion
criterion in 56 trials. Of these, 51 included patients with
severe head injury, 17 included patients with moderate
head injury, and eight trials included patients with mild
head injury. A total of 126 trials assessed the effect of
the trial intervention on the extent of disability. The
most commonly used outcome measure was the Glas›
gow outcome scale, used in 45% of trials assessing dis›
ability. Of the 126 trials assessing disability, 111
reported the number of patients followed up. In those
trials, the average loss to follow up was 19%. Of the
trials measuring disability, only 26 (21%) reported that
the outcome assessors had been blinded.
Discussion
There is a growing recognition that large absolute
reductions in death or disability cannot realistically be
expected in the treatment of head injury.5 Changes in
outcome of “only” a few per cent would nevertheless be
important, especially if achievable with widely practica›
ble treatments. To detect such moderate treatment
effects, both moderate random errors and moderate
biases must be avoided.
Table 1 Number of trials and number of randomised
participants by intervention
Category
No of
trials*
No of
participants
Aminosteroid 3 1331
Anaesthetics 27 1010
Antidepressant 3 26
Antiseizure 8 (1) 1212
Antispasticity 2 12
Antiulcer 5 354
â blockers 2 135
Calcium antagonists 5 1405
Cognitive therapy 8 406
Corticosteroids 23 (1) 2515
Dimethyl sulfoxide 1 35
Endocrine 5 258
Fluid therapy 4 (1) 127
Hypothermia 9 364
Management and information 7 2280
N›methyl›D›aspartate antagonists (eliprodil, cerestat) 2 485
Nootropics (piracetam, pramiracetam sulphate) 3 123
Nutrition 24 (2) 854
Osmotic diuretics 3 140
Other 20 (1) 665
Polyethylene glycol›superoxide dismutase 2 567
Phospholipids (CDP›Choline) 4 (1) 350
Pyritinol hydrochloride 3 370
Physical therapy 8 (1) 364
Stimulant (methylphenidate, amphetamine) 10 215
TRIS 4 411
Vasopressin 3 36
Ventilation 10 563
*Number of trials that included patients with mild head injury on Glasgow
coma scale given in brackets.
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Failures of existing research
The results of our review suggest that currently available
trials in head injury fail on both counts. Most trials of
head injury are small. The average number of
randomised participants was 82, and the largest trial
included only 1156 participants. None of the trials
would have been large enough to detect reliably the dif›
ference between a 20% and a 15% risk of death or
disability. If baseline risk was higher than 20%, then
existing trials would have even lower power to detect any
given absolute reduction in the risk of death or disability.
The concern about the small size of trials is as rel›
evant for minor head injury as it is for the more severe
injuries. Three months after sustaining minor head
injury, 79% of patients have persistent headaches, 59%
have memory problems, and 34% of previously
employed people are still unemployed.6 If a treatment
reduced the risk of memory loss, headache, and unem›
ployment by 5% then this would be an important
discovery. Most trials, however, would miss this. More›
over, for any given category of therapeutic agent the
total number of randomised participants was at most a
few thousand. Thus, even in aggregate, existing trials
are too small to support or refute the possibility of
moderate harm or moderate benefit. This is of particu›
lar importance given that most, if not all, of the
pharmacological interventions currently used in the
management of severe head injury are of unproved
benefit.7 The paucity of trials in head injury is
underscored by the fact that the total number of
randomised participants in all of the available trials in
head injury combined (16 613) is less than that in some
individual trials in heart disease and stroke.8–10
The effect of poorly concealed random allocation
can be as large as or larger than the effect of the treat›
ment under investigation and can operate in either
direction,11 yet only 23% of the trials reported the
method of allocation concealment, and concealment
was judged to be adequate in only half of these. We did
not contact authors for further information in trials in
which concealment of allocation was unclear, as
experience with systematic reviews in this topic has
shown that additional information can be obtained for
only a small proportion of trials. Furthermore, there is
evidence to suggest that it is rare for information to be
omitted that would change the classification.12
Despite extensive efforts to include as many trials as
possible, those that we identified are best considered as a
sample of the currently available head injury trials.
Because the sample was obtained by systematically
searching mainstream medical databases and medical
journals there is no reason to suspect that large or good
quality trials would have been underrepresented. The
chances that we have overlooked a substantial body of
large, high quality trials is remote. Although it is inevita›
ble that we have missed some trials, we would not expect
health professionals caring for patients with head injury
to have ready access to more trials than we have found.
Problems leading to failure
Why is it that those who provide care for patients with
head injury have such a meagre evidence base on which
to draw? Two factors in particular may be important.
Firstly, in comparison with the burden of disability, fund›
ing for injury research is less than for almost any other
cause of human misery,13 perhaps because there are
fewer advocates for research in head injury than for
cardiovascular disease or cancer. Secondly, people with
head injury and impaired consciousness are unable to
give informed consent. They present an important
exception to the general requirement to obtain
informed consent in clinical research.14 Nevertheless,
many ethics committees and investigators are unfamiliar
with the idea of randomisation without consent, and the
resulting confusion has been an important obstacle to
enrolment. It was concern that safer and more effective
interventions for life threatening emergencies were not
being developed because of the need to obtain informed
consent, however, that stimulated the US Department of
Health and Human Services to announce in 1995 a
waiver of requirements for informed consent in certain
emergency research.15 It will be interesting to see
whether, over the next decade or so, this has the hoped
for effect on trial size.
Road traffic accidents account for most serious
head injuries, and with increasing motorisation the
global burden of head injuries can only be expected to
increase. It is estimated that by 2020 road traffic
accidents will be the third leading cause of disability›
adjusted life years lost worldwide and the second lead›
ing cause in developing countries. Currently, many
millions of patients are treated each year for severe
head injury, and there are few treatments of established
effectiveness. If a widely practicable treatment reduced
the risk of death or disability by 5%, then treatment of
What is already known on this topic
Millions of people are treated each year for head injury, a substantial
proportion of whom die and many more are permanently disabled
If a widely practicable treatment could be shown to reduce the absolute
risk of death and disability by just a few per cent, then, because this
might affect the treatment of hundreds of thousands of patients, it
could protect thousands from death or disability
To detect reliably such modest treatment effects, head injury trials must
be large and well designed
What this study adds
The results of this survey of randomised controlled trials in head injury
show that currently available trials are too small and too poorly
designed to be able to detect or refute reliably realistically modest but
clinically important benefits or hazards
Large randomised controlled trials of widely practicable treatments for
head injuries are needed
Table 2 Method of allocation in trials in which it was reported
Method No of trials
Centralised randomisation by telephone* 1
Numbered/coded identical containers administered sequentially* 11
Randomisation scheme controlled by pharmacy* 8
Sequentially numbered, sealed, opaque envelopes* 2
Other† 18
Date of birth 1
Day of week 3
Alternation 3
*Methods of allocation judged to be adequately concealed.
†Ten of 18 trials involved use of envelopes but did not specify if they were
sequentially numbered, sealed, or opaque.
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one million patients would protect 50 000 people from
death or disability. Large scale randomised controlled
trials have the potential to make an important
contribution to the prevention of death and disability
from this growing epidemic.16 17
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Suicidal ideation among outpatients at general neurology
clinics: prospective study
Alan J Carson, Steven Best, Charles Warlow, Michael Sharpe
Suicide is one of the ten most common causes of death
for both men and women in Great Britain.1 Psychiatric
disorders are the main risk factor, but numerous studies
have also identified physical illness as an important con›
tributory factor.1 2 Although it is considered mandatory
to enquire about suicidal ideation in psychiatric consul›
tations, this is seldom part of a medical assessment. We
aimed to examine suicidal ideation in a consecutive
series of patients who had been newly referred to
general neurology outpatient clinics. The study was
approved by the local research ethics committee.
Participants, methods, and results
As part of another study,3 300 of 312 consecutive new
patients at the general neurology outpatient clinics at
the Western General Hospital, Edinburgh, were
interviewed using the primary care evaluation of men›
tal disorders (PRIME›MD) structured psychiatric inter›
view schedule.4 As part of the interview all patients
were asked: “In the last two weeks, have you had
thoughts that you would be better off dead or of hurt›
ing yourself in some way?”
Patients who answered yes were asked to describe
the nature of these thoughts. To be classed as
experiencing suicidal ideation the patient had to have
thought about active plans for committing suicide—
such as buying tablets—nearly every day for the
previous two weeks. Whenever a patient reported such
ideation the general practitioner was informed.
Diagnoses of anxiety and depressive disorders that
were made using the structured interview were also
recorded. After the clinical consultation, the neurolo›
gists recorded the neurological diagnosis and whether
the patient required psychiatric or psychological
assessment or treatment.
Before a patient attended the clinic the patient’s
general practitioner was sent a brief questionnaire. The
general practitioners were asked to indicate whether
they believed that the patient required psychiatric or
psychological assessment or treatment.
At the time of assessment the researchers were
blind to the opinions of the neurologists and the
general practitioners.
The clinical characteristics of the patients attending
the clinics are shown in the table. One in 11 patients
(26/300) seen at the general neurology clinics had
given serious thought to committing suicide in the past
two weeks. Almost all of these patients (23/26) had
major depression. It might be assumed that suicidal
ideation would be more likely to occur in patients with
progressive, debilitating neurological conditions. How›
ever, this was not the case. Twelve of the 26 patients
who had experienced suicidal ideation had medically
unexplained symptoms, and most of the remainder
had non›progressive conditions.
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